Back to Results

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

Interested in this Trial?

Contact Us

Trial Status Recruiting

Trial Identifier

NCT05813678

Condition

Phenylketonuria, Phenylketonuria (PKU)

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment (incident-users) or have previously started treatment with pegvaliase at the date of enrollment (prevalent-users) are eligible for participation in this study.

Eligibility Criteria

Birth Sex

All

Age

Any

Healthy Volunteers

No

Drug/Treatment:

Pegvaliase

Study Type:

Observational

Number of Participants:

450

Study Started:

2022-06-06

Study Updated:

2024-05-13

Trial Locations

  • University of Colorado

    Aurora, Colorado, United States

  • Northwestern University

    Chicago, Illinois, United States

  • Indiana University School of Medicine

    Indianapolis, Indiana, United States

  • Tulane University Medical Center

    New Orleans, Louisiana, United States

  • Oregon Health and Science University

    Portland, Oregon, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

  • Hospital Carl-Thiem-Klinikum Cottbus

    Cottbus, , Germany

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, , Germany

  • Universitätsklinikum Münster (UKM)-Pädiatrische Universitätsklinik Münster

    Münster, , Germany

  • Universität Ulm

    Ulm, , Germany

  • Policlinico Sant'orsola Malpighi

    Bologna, , Italy

  • University Hospital Careggi

    Firenze, , Italy

  • Ospedale San Paolo

    Milan, , Italy

  • Azienda Ospedaliera Universitaria "Federico II" Dipartimento di Pediatria

    Naples, , Italy

Inclusion Criteria

  • Documented diagnosis of PKU per local standard of care
  • Currently receiving or planned to receive pegvaliase treatment within 30 days after the date of enrollment, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation.
  • Subject (or legally authorized representative) is willing and able to provide written informed consent after the nature of the study has been explained and prior to any data collection.

Exclusion Criteria

  • Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with any aspect of the study.
  • Currently participating in an interventional study of any investigational product, device, or procedure
  • Previously enrolled in this study (eg, subjects who have been withdrawn from the study and wish to participate again at a later date)
  • German subjects <16 years if ag

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us